Iterum Expects To Start Additional Sulopenem Trial In Urinary Tract Infections In 2H22

By: via Benzinga
Iterum Therapeutics plc(NASDAQ: ITRM) has incurred aQ4 FY21 EPS loss of $(0.02)versus $(0.28) reported a year ago and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.